Organic Active Ingredients TRIZ Cases

Fused heterocyclic derivatives bind capsid proteins to disrupt assembly, suppressing production while avoiding drug resistance.

Combining epidermal growth factor with chitosan and hyaluronic acid to treat pulmonary fibrosis.

Analyzing miR-320e expression guides treatment selection, reducing drug toxicity while improving therapeutic effectiveness in colorectal cancer.

Encapsulation protects docosahexaenoic acid from oxidation, maintaining stability without preservatives.

Substituted spiro[cycloalkyl-1,3'-indol]-2'(1'H)-one derivatives inhibit p38 kinase activity with high potency.

Combining ERK 1/2 and JAK inhibitors reduces splenomegaly and bone marrow fibrosis while improving anemia in myelofibrosis patients.

Selexipag polymorphs and solvates resolve processing trade-offs to boost bioavailability.

Targeting specific nocipoints with electrical or chemical stimuli activates stem cells to heal chronic skeletal-muscular injuries and restore function.

HLA-G antibody-conjugated extracellular vesicles cross the blood-brain barrier to target glioblastoma cells, overcoming MGMT-mediated drug resistance.

A nutraceutical composition combines L-tryptophan with niacin, vitamin B6, and magnesium to stimulate metabolic conversion.

Segmenting virus detection from renal prognosis using FGF2 and Smad7 markers resolves inadequate diagnostic precision.

A medical device coating layer applies a hydrophobic therapeutic agent over a plasma-polymerized intermediate surface.

Segmented ring opening and closing of phragmalin lactone intermediates overcomes low yield and side product formation from conventional isolation.

Once-daily bupropion and dextromethorphan dosing reduces somnolence risk in moderate renal impairment while maintaining therapeutic efficacy.

Conformationally-constrained peptidomimetic inhibitors bind 3CL protease active sites to block viral replication.

Hypotonic formulations overcome the mucus barrier by driving mucus-penetrating nanoparticles to epithelial surfaces via osmotic gradients.

Antibodies with specific heavy and light chain variable regions activate OX40 receptors to drive CD4+ T cell proliferation.

A nimodipine parenteral solution uses hydrophilic surfactants to form micelles that solubilize the drug in aqueous media.

Specific crystal forms of a pyrimidine sulfonamide compound achieve over 10,000-fold ETA selectivity to minimize hepatotoxicity risks.

Exosome-like decoctosomes extract active small RNAs from herbal medicines using differential centrifugation and lipid heating.

Regulating API particle size to 80-300 μm resolves the trade-off between high bioavailability and tablet hardness in composite oral formulations.

Fixed dose pertuzumab and trastuzumab formulations combined with rHuPH20 enzyme for subcutaneous delivery.

Polyoxyethylene castor oil prevents degradation of pyridylaminoacetic acid during long-term storage in aqueous formulations.

Acrylic polymer matrix with penetration enhancers sustains levonorgestrel and ethinyl estradiol delivery while preventing crystallization.

Short activating RNA molecules target HNF4a transcripts to resolve precision-reliability trade-offs in metabolic disorder treatments.

A stable solid oral dosage form containing fingolimod rapidly dissolves in the oral cavity using sugar alcohols and moisture facilitating compounds.

Unsubstituted thiazolo[5,4-d]pyrimidine derivatives deliver potent immunosuppressive effects against inflammatory disorders where existing agents lack efficacy.

Quaternary carbon stereogenic centers at the 3' position of tetrahydrofuranyl nucleotides improve cancer specificity and stability.

Tetrahydropyranol derivatives mitigate neuronal damage by inhibiting tau aggregation and reducing caspase 3 activity.

siRNAs silence galectin-3 to reduce complex cytokine network modulation, alleviating inflammatory diseases.

Butylidenephthalide inhibits autophagy in motor neurons to delay disease progression.

Amylase enzymes cleave glycosidic bonds in polysaccharides to remove necrotic tissue, avoiding allergic events and auto-digestion.

Replacing castor oil with benzyl alcohol and ethanol reduces injection site irritation while allowing higher doses in smaller volumes.

KM-819 salt forms delay tissue injury and protect cardiomyocytes by optimizing solubility to address reperfusion damage.

Substituted piperidine compounds selectively modulate orexin receptors, resolving the trade-off between therapeutic efficacy and side effects.

N-acetylcysteine and B vitamins bypass liver degradation to raise brain glutathione, enhancing mental energy.

DA1229 inhibits DPP-IV to prevent nephrin degradation, resolving unknown mechanisms in diabetic nephropathy treatment.

Rapamycin blocks mTOR functions to induce autophagy, preventing aminoglycoside-induced ototoxic hearing loss without systemic antioxidant side effects.

Genotyping INHBE variants enables precise inhibitor dosing to manage type 2 diabetes and cardiovascular disease risks.

Macrocyclic indole derivatives overcome chemoresistance by inhibiting MCL-1 protein activity and restoring apoptotic signaling in cancer cells.

Formula I compounds achieve selective RET inhibition to reduce off-target toxicities while maintaining efficacy against resistant mutants.

Ritonavir boosts lonafarnib bioavailability by inhibiting CYP3A4 metabolism, resolving low systemic exposure while maintaining therapeutic efficacy.

Computational screening extracts the binding function of large PEDF protein into stable small molecules, resolving size and stability trade-offs.

Nanometric liposomes deliver siRNA across the blood-brain barrier to silence CD73, reducing glioblastoma progression without systemic toxicity.

Stable 127I precursors undergo palladium-catalyzed isotopic exchange to produce iodine-labeled choline analogs, eliminating on-site cyclotron requirements.

Pyrido[2,3-d]pyrimidine derivatives target the HIV capsid to overcome viral resistance and toxicity while maintaining potent replication inhibition.

Transdermal buffering patches neutralize inflammatory acidity to lower C-Reactive Protein concentrations while preventing bone decalcification.

DPI-125 acts on mu, delta, and kappa opioid receptors to provide potent analgesia.

Humic acid from Sphagnum extracts suppresses macrophage activation and cytokine production.

Oligonucleotides targeting RORC2 mRNA inhibit ROR gamma t expression, resolving off-target effects from non-selective agents.

Repurposing Raloxifene provides rapid antiviral activity against emerging SARS-CoV-2 variants, bypassing lengthy drug development processes.

TGF-beta 1 inhibitors block viral NSP15 activation, resolving immune suppression and reducing acute respiratory distress syndrome severity.

Anhydrous solvent process creates powder solid dispersions to resolve poor water solubility and inconsistent oral bioavailability.

FU-LING extract and tumulosic acid delay muscle atrophy by regulating protein synthesis and satellite cell activation.

Molecular marker analysis differentiates eosinophilic esophagitis from GERD, ensuring appropriate targeted therapy selection.

Colchicine-binding site compounds inhibit tubulin polymerization to treat cancer.

Pyrrolo[3,2-d]pyrimidine compounds inhibit RIPK2 to suppress cancer progression and inflammatory responses.

Emulsification-based fabrication deposits phosphatidylserine on PLG particle surfaces, resolving off-target effects while maintaining controlled drug release.

Synthetic microparticles replicate dendritic cell functions to eliminate ex-vivo manipulation risks while sustaining immune tolerance.

Segmented Volasertib dosing on days 1 and 8 improves anti-tumor efficacy while managing toxicity.

Bioabsorbable naltrexone implant prevents opioid relapse by sustaining therapeutic serum concentrations over extended periods.

Isotopic labeling and mathematical modeling quantify NADPH metabolism to resolve measurement precision limits in cancer diagnostics.

Modulating SARM1 activity reduces axonal and synaptic degradation in neurons.

BRD4 and CDK9 inhibitors block epithelial-mesenchymal transition, reducing fibrosis progression in chronic lung diseases.

Co-formulating rapid-acting insulin with pramlintide at pH 3.0 to 4.4 stabilizes the mixture for pump use while suppressing post-meal glucagon spikes.

Substituted triazole compounds inhibit LPA receptors to address fibrosis progression.

Polymeric sugar wraps DHA oil particles in an oxygen-isolated honeycomb structure, reducing oxidation rates and eliminating fishy odors during storage.

Carnauba wax base replaces synthetic excipients to resolve stability versus purity trade-offs.

Oligonucleotides downregulate Map4k4 mRNA in endothelial cells, reducing leukocyte extravasation and fluid leakage from blood vessels.

Combining paclitaxel with 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine enhances anti-tumor effects.

Periodic dosing cycles of JNJ-64619178 maintain pharmacodynamic modulation while reducing toxicity accumulation in cancer treatment.

A Gottingen miniswine model integrates Western diet and DOCA-salt to induce hypertension.

Novel autotaxin inhibitor compounds suppress lysophosphatidic acid levels to treat cancer, fibrosis, and inflammatory disorders.

Inhaled dry powder delivers GLP-1 into pulmonary alveolar capillaries, bypassing peripheral degradation and reducing nausea or vomiting.

A fused-ring heterocyclic compound inhibits Wnt signaling via tankyrase interaction to treat malignancies.

A niosome nano-carrier topical composition moves Vitamin D3 through the skin barrier into systemic circulation.

Developing specific polymorphic forms resolves formulation complexity while ensuring consistent bioavailability and shelf life.

Plant-derived miR172 molecules interact with mRNA encoding the FAN protein to negatively regulate its expression.

A nanoparticle nanosystem encapsulating leriglitazone and siRNA targets SARS-CoV-2 infection through linoleic acid surface coating.

Phenyl-pyrimidinyl-urea derivatives inhibit Olig2 activity to target glioblastoma stem cells.

Ethanol precipitation isolates polymannan fractions that elevate caspase 3 levels and increase natural killer cells to induce apoptosis in cancer cells.

H-indole-pyridinecarboxamide derivatives induce tyrosine hydroxylase for neurotransmitter synthesis.

Ileal bile acid reuptake inhibitors boost GLP-1 secretion via FGF15/19 signaling, resolving glucose control and side effect trade-offs.

A regenerative composition uses alginic acid gel to embed mesenchymal stem cells for nucleus pulposus repair.

Combining diuretics with vessel dilator peptides overcomes resistance and kidney damage in heart failure.

Low water activity in aerated erythritol foam prevents degradation while enabling high active ingredient loading.

4-Phenyl indole derivatives replace monoclonal antibodies to overcome complex administration protocols while restoring T cell activation.

Static magnetic fields activate 13C-labeled isoniazid to maximize toxic adduct formation, reducing bacterial dormancy and improving treatment efficacy.

Reverse thermal gelation extends mitomycin dwell time in the bladder, reducing tumor recurrence risk compared to TURBT monotherapy.

BGJ398 downregulates FGFR3 phosphorylation, reversing learning deficits caused by gain-of-function mutations.

Functionalized nanodiamond particles adsorb water-insoluble therapeutics, enabling aqueous dispersion and improved bioavailability.

A bispecific antibody-drug conjugate binds EGFR and c-MET receptors to deliver cytotoxic payloads directly to tumor cells.

Cyclic oligosaccharides encapsulate fragrances within their cavities, reducing premature evaporation and extending scent longevity without nonvolatile solvents.